Key result
ACS patients face a ~29% cumulative incidence of MACE during long-term follow-up.
Why the study?
Data on long-term outcomes after hospitalization for ACS are limited, prompting the need to estimate the rate of recurrent cardiovascular events in an unselected population.
Cohort (n=1,379)
No
The risk of recurrent cardiovascular events remains high up to 5 years after an acute coronary syndrome, highlighting the need for sustained secondary prevention.
High recurrent MACE rates over 5 years post-ACS suggest sustained secondary prevention may be needed; leaves open optimal long-term strategies.
IntroductionThere is limited data on long-term outcomes after hospitalization for ACS. We aimed to estimate the rate of recurrent cardiovascular events in the long-term, in a population-based, unselected cohort of ACS patients.Methods and resultsWe included 1379 patients with ACS hospitalized at Östersund hospital 2010-2014 and followed them from the day after discharge to 31 December 2017. The primary endpoint was the unadjusted rate of the composite of CV death, AMI and ischemic stroke. Risk factors for the primary endpoint were assessed in a multivariable Cox proportional hazards regression model. During a median follow-up of 4.7 years, the unadjusted rate of the primary endpoint was 10.3% at 1 year and 28.6% at the end of follow-up. Predictors of increased risk for subsequent events were congestive heart failure, diabetes mellitus, angina pectoris, prior revascularization with PCI or CABG and treatment with diuretics at discharge. Lipid-lowering therapy at discharge and revascularization with PCI or CABG were associated with a lower risk of recurrent events.ConclusionThe risk of recurrent cardiovascular was high at 1 year and continued to be so during the following almost three years of median follow-up. Established predictors of cardiovascular risk were confirmed.
No takes yet. Share an insight, caveat, or question.
Ulvenstam et al. (2022) conducted a cohort in Acute Coronary Syndrome (n=1,379). Acute coronary syndrome patients experienced a 28.6% cumulative incidence of major adverse cardiovascular events over a median follow-up of 4.7 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: